Research News

FDA Approves Genentech’s Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer

Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from a study that showed... 

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic... 

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months... 

Diet May Influence Ovarian Cancer Survival

According to a new study published in the Journal of the National Cancer Institute, a good diet before diagnosis is linked with lower mortality among ovarian cancer survivors. Researchers analyzed data from 636 cases of ovarian cancer among postmenopausal women within the Women’s Health Initiative... 

Use of Intensive Medical Services for Ovarian Cancer Patients at End of Life Increases Despite Rise in Use of Hospice

There have been widespread efforts to improve the quality of life of terminally ill patients. As more patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A large new study by Dana-Farber... 

Telomere Length and Mortality Following An Ovarian Cancer Diagnosis

Telomeres are essential for the maintenance of chromosomal integrity. Telomere shortening leads to genomic instability, which is hypothesized to play a role in cancer development and prognosis. New data published in Cancer Epidemiology, Biomarkers & Prevention, provide preliminary evidence that telomere... 

Detection of Gene Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer

(October 14, 2014) In a pilot study published in the journal Obstetrics & Gynecology, researchers detected DNA derived from tumor cells in the vaginas of 60% of patients with ovarian cancer with intact fallopian tubes. With further development, this approach may hold promise for the early detection... 

Ovarian Cancer Oncogene Found in ‘Junk DNA’

(October 6, 2014) A research team based at the University of Pennsylvania mined junk DNA sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer.  The study, which was published in Cancer Cell, was supported in part by an OCRF research grant to Lin Zhang, MD. The... 

SGO Perspectives on Endpoints for Studies of Ovarian Cancer

(Sept. 29, 2014) In a perspective piece for the website MedPage Today, representatives from the Society of Gynecologic Oncology discuss clinical endpoints appropriate for studies addressing the “unique characteristics” of ovarian cancer and progress toward improving outcomes for women affected... 

Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High Rate of Complications

(Sept. 25, 2014) Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical...